Laboratoires Euromedis Société anonyme Full Year 2024 Earnings: Revenues Beat Expectations

Laboratoires Euromedis Société anonyme (EPA:ALEMG) Full Year 2024 Results

Key Financial Results

• Revenue: €40.3m (up 7.6% from FY 2023).
• Net loss: €6.11m (down by 147% from €13.1m profit in FY 2023).

We've discovered 1 warning sign about Laboratoires Euromedis Société anonyme. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Laboratoires Euromedis Société anonyme Revenues Beat Expectations

Revenue exceeded analyst estimates by 1.3%.

Looking ahead, revenue is expected to decline by 1.1% p.a. on average during the next 2 years, while revenues in the Medical Equipment industry in France are expected to grow by 6.2%.

Performance of the French Medical Equipment industry.

The company's shares are up 9.2% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Laboratoires Euromedis Société anonyme has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.